CH BIOTECH SER (08037) announced its mid-term results, with a profit attributable to shareholders of HKD 18.23 million, turning from a loss to a profit compared to the same period last year.

01:20 29/08/2026

China Biotechnology Services (08037) announced its interim results for the six months ended June 30, 2026. The group achieved revenue of HKD 37.226 million, a year-on-year increase of 49.71%; the profit attributable to the owners of the company was HKD 18.23 million, shifting from loss to profit year-on-year; earnings per share were HKD 0.03.

CH BIOTECH SER (08037) announced its interim results for the six months ended June 30, 2026, reporting revenue of HKD 37.226 million, an increase of 49.71% year-on-year; profit attributable to the owners of the company was HKD 18.23 million, turning from loss to profit year-on-year; earnings per share were HKD 0.03. The announcement stated that the increase in revenue was primarily driven by the trial operations of the Pengbo (Hainan) Boron Neutron Hospital (Boron Neutron Capture Therapy Center) which began in February 2026, as well as revenue of approximately HKD 26.7 million from providing boron neutron capture therapy services.

After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."

Electra Therapeutics (ETRA.US) has submitted an IPO application for the U.S. stock market, leveraging the current biotech IPO boom to advance the development of new drugs for immune diseases and cancer.

Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).

After Cursor was acquired by SpaceX (SPCX.US), OpenAI announced the termination of cooperation citing Musk's "breach of contract history."

Blue Owl (OWL.US) has teamed up with PIMCO to customize a $2.4 billion GPU financing for IREN (IREN.US).